RG6662 / Roche - LARVOL DELTA

Next Steps (Roche Press Release) - "Communications to Study Participants: Our immediate focus is supporting participants and sites regarding these announcements. Earlier this week, sites were notified so they could contact participants and discuss transition plans and support...Sharing Data & Learnings: Data will continue to be analysed and presented at future medical meetings. We are committed to sharing learnings with the research and family communities to advance the understanding of drug development for HD; Further Research: Roche’s Phase I/II study of investigational gene therapy RG6662 (formerly from Spark Therapeutics; study SPK-101, NCT06826612) is ongoing as planned. Additionally our interest in exploring multiple HD therapeutic approaches remains, and we will continue to follow promising science."

P1 data • P2 data • Trial status • CNS Disorders • Huntington's Disease

Huntington's disease clinical trials update: October 2025. (PubMed, J Huntingtons Dis) - "In this edition of the Huntington's Disease Clinical Trials Update, we expand on the launch of the phase II/III clinical trial of SKY-0515 from Skyhawk Therapeutics and the phase I/II clinical trial of SPK-10001 from Spark Therapeutics. Further updates include recent developments in Roche's tominersen programme within GENERATION HD2, progress with votoplam (PTC518) in PIVOT-HD by PTC Therapeutics and developments in the collaborative PTC Therapeutics/Novartis programme. We also report positive topline data from uniQure's phase I/II clinical trial of AMT-130 after 36 months of follow-up. We additionally discuss regulatory developments regarding pridopidine following the negative PROOF-HD study. Finally, we provide an updated listing of all registered and ongoing clinical trials in Huntington's disease."

Journal • Huntington's Disease • Movement Disorders